US lab operator Quest Diagnostics to launch bird flu test at end of October
Oct 23 -Lab operator Quest Diagnostics DGX.N said on Wednesday it will launch a test for H5N1 bird flu at the end of October after the U.S. Centers for Disease Control and Prevention (CDC) gave it contracts to support testing for two emerging infectious diseases, including the Oropouche virus.
WHY IT'S IMPORTANT
The spread of bird flu among dairy herds and infections of 27 people this year have alarmed some public health experts.
More than 100 million U.S. chickens, turkeys and other birds have been eliminated by the virus since the outbreak began in 2022.
The CDC says that this year, there have been 91 cases of the Oropouche virus, which spreads primarily through bites from midges as well as from some mosquitoes.
Last month, the CDC issued a health alert to notify clinicians and public health authorities of an increase in Oropouche virus cases in the Americas region that has caused two deaths so far this year.
CONTEXT
Besides Quest, the CDC is working with four laboratory companies, including Aegis, ARUP, Ginkgo BioWorks DNA.N and Labcorp LH.N, to develop tests for health outbreaks.
This will support the country's preparedness for these threats by ensuring a commercial laboratory provider is able to supplement public health laboratories in case of an outbreak in people.
The CDC contract also provides Quest with funds to maintain testing readiness, such as for adequate supplies of equipment and chemical reagents used to perform the tests.
WHAT'S NEXT
Quest's bird flu test will be available with a prescription.
Its laboratory in San Juan Capistrano, California, which developed the test, will also conduct the test.
The test is intended to be performed using respiratory specimens or specimens of the outer membrane of eyes collected from people suspected of having the virus, or who meet the CDC's testing criteria.
Reporting by Puyaan Singh in Bengaluru; Editing by Savio D'Souza
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
